Trained immunity modulates inflammation-induced fibrosis

Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428–435 (2008).

Wynn, T. A. & Barron, L. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 30, 245–257 (2010).

Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028–1040 (2012).

Meng, X.-M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-β: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325–338 (2016).

Novak, M. L. & Koh, T. J. Phenotypic transitions of macrophages orchestrate tissue repair. Am. J. Pathol. 183, 1352–1363 (2013).

Netea, M. G. & van der Meer, J. W. M. Trained immunity: an ancient way of remembering. Cell Host Microbe 21, 297–300 (2017).

Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).

Quintin, J. et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223–232 (2012).

Arts, R. J. W. et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep. 17, 2562–2571 (2016).

Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl Acad. Sci. USA 109, 17537–17542 (2012).

Kleinnijenhuis, J. et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J. Innate Immun. 6, 152–158 (2014).

Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30, 475–487 (2009).

Döcke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3, 678–681 (1997).

Shnyra, A., Brewington, R., Alipio, A., Amura, C. & Morrison, D. C. Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. J. Immunol. 160, 3729–3736 (1998).

Cheng, S.-C. et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat. Immunol. 17, 406–413 (2016).

Novakovic, B. et al. β-glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354–1368.e14 (2016).

Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).

Arts, R. J. W., Joosten, L. A. B. & Netea, M. G. Immunometabolic circuits in trained immunity. Semin. Immunol. 28, 425–430 (2016).

Seeley, J. J. & Ghosh, S. Molecular mechanisms of innate memory and tolerance to LPS. J. Leukoc. Biol. 101, 107–119 (2017).

Arts, R. J. W., Joosten, L. A. B. & Netea, M. G. The potential role of trained immunity in autoimmune and autoinflammatory disorders. Front. Immunol. 9, 298 (2018).

Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Primers 1, 15002 (2015).

Chia, J. J. & Lu, T. T. Update on macrophages and innate immunity in scleroderma. Curr. Opin. Rheumatol. 27, 530–536 (2015).

Morell, M., Varela, N. & Marañón, C. Myeloid populations in systemic autoimmune diseases. Clin. Rev. Allergy Immunol. 53, 198–218 (2017).

Stifano, G. & Christmann, R. B. Macrophage involvement in systemic sclerosis: do we need more evidence? Curr. Rheumatol. Rep. 18, 2 (2016).

Waldner, H. The role of innate immune responses in autoimmune disease development. Autoimmun. Rev. 8, 400–404 (2009).

Hu, M. et al. Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer. Hum. Pathol. 46, 1872–1880 (2015).

Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004).

Sahin, H. & Wasmuth, H. E. Chemokines in tissue fibrosis. Biochim. Biophys. Acta 1832, 1041–1048 (2013).

Maeda, S. et al. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production. Am. J. Pathol. 179, 2360–2369 (2011).

Conde, P. et al. DC-SIGN(+) macrophages control the induction of transplantation tolerance. Immunity 42, 1143–1158 (2015).

Italiani, P. & Boraschi, D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front. Immunol. 5, 514 (2014).

Wang, T. et al. Subsequent infections in survivors of sepsis: epidemiology and outcomes. J. Intensive Care Med. 29, 87–95 (2014).

Ishikawa, O. & Ishikawa, H. Macrophage infiltration in the skin of patients with systemic sclerosis. J. Rheumatol. 19, 1202–1206 (1992).

Yoshizaki, A. et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J. Immunol. 185, 2502–2515 (2010).

Varga, J. & Abraham, D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557–567 (2007).

Lee, R. et al. Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1. Fibrogenes. Tissue Repair 8, 11 (2015).

Lescoat, A. et al. CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis. Clin. Rheumatol. 36, 1649–1654 (2017).

Weigold, F. et al. Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. Arthritis Res. Ther. 20, 52 (2018).

Gibbons, M. A. et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am. J. Respir. Crit. Care Med. 184, 569–581 (2011).

Hartl, D. et al. A role for MCP-1/CCR2 in interstitial lung disease in children. Respir. Res. 6, 93 (2005).

Kitagawa, K. et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am. J. Pathol. 165, 237–246 (2004).

Moore, B. B. et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. Baltim. 167, 4368–4377 (2001).

Okuma, T. et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J. Pathol. 204, 594–604 (2004).

Seki, E. et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 50, 185–197 (2009).

Wolf, S., Johnson, S., Perwitasari, O., Mahalingam, S. & Tripp, R. A. Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment. Clin. Transl. Immunol. 6, e135 (2017).

Sánchez-Martín, L. et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117, 88–97 (2011).

Tanaka, C. et al. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway. Arthritis Rheum. 62, 1723–1732 (2010).

Cox, N., Pilling, D. & Gomer, R. H. DC-SIGN activation mediates the differential effects of SAP and CRP on the innate immune system and inhibits fibrosis in mice. Proc. Natl Acad. Sci. USA 112, 8385–8390 (2015).

Nakagome, K. et al. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 61, 886–894 (2006).

Basu, J., Shin, D.-M. & Jo, E.-K. Mycobacterial signaling through toll-like receptors. Front. Cell. Infect. Microbiol. 2, 145 (2012).

O’Neill, L. A. J. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353–364 (2007).

Bhattacharyya, S. et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight 3, 98850 (2018).

Stifano, G. et al. Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis. Arthritis Res. Ther. 16, R136 (2014).

Song, E. et al. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell. Immunol. 204, 19–28 (2000).

Kechagia, J. Z., Ezra, D. G., Burton, M. J. & Bailly, M. Fibroblasts profiling in scarring trachoma identifies IL-6 as a functional component of a fibroblast-macrophage pro-fibrotic and pro-inflammatory feedback loop. Sci. Rep. 6, 28261 (2016).

O’Sullivan, T. E., Sun, J. C. & Lanier, L. L. Natural killer cell memory. Immunity 43, 634–645 (2015).

Martinez-Gonzalez, I., Mathä, L., Steer, C. A. & Takei, F. Immunological memory of group 2 innate lymphoid cells. Trends Immunol. 38, 423–431 (2017).

Li, H., You, H., Fan, X. & Jia, J. Hepatic macrophages in liver fibrosis: pathogenesis and potential therapeutic targets. BMJ Open Gastroenterol. 3, e000079 (2016).

Tacke, F. Targeting hepatic macrophages to treat liver diseases. J. Hepatol. 66, 1300–1312 (2017).

Thomas, J. A. et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology 53, 2003–2015 (2011).

François, A. et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res. Ther. 15, R168 (2013).

Vancheri, C. et al. Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells. Respir. Res. 6, 103 (2005).

Matsushita, Y. et al. Intercellular adhesion molecule-1 deficiency attenuates the development of skin fibrosis in tight-skin mice. J. Immunol. 179, 698–707 (2007).

Josefsen, K., Nielsen, H., Lorentzen, S., Damsbo, P. & Buschard, K. Circulating monocytes are activated in newly diagnosed type 1 diabetes mellitus patients. Clin. Exp. Immunol. 98, 489–493 (1994).

Gjelstrup, M. C. et al. Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis. Immunol. Cell Biol. 96, 160–174 (2018).

Li, Y., Lee, P. Y. & Reeves, W. H. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch. Immunol. Ther. Exp. (Warz.) 58, 355–364 (2010).

Vogel, D. Y. et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflammation 10, 35 (2013).

Alkanani, A. K. et al. Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. Diabetes 61, 2525–2533 (2012).

Steinbach, F. et al. Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility. Ann. Rheum. Dis. 59, 283–288 (2000).

Lioté, F., Boval-Boizard, B., Weill, D., Kuntz, D. & Wautier, J. L. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release. Clin. Exp. Immunol. 106, 13–19 (1996).

Zhang, S. et al. Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway. Int. J. Clin. Exp. Pathol. 7, 6626–6634 (2014).

Bartosh, T. J. & Ylostalo, J. H. Macrophage inflammatory assay. Bio Protoc. 4, e1180 (2014).

Wang, C. et al. Characterization of murine macrophages from bone marrow, spleen and peritoneum. BMC Immunol. 14, 6 (2013).

Brubaker, A. L., Schneider, D. F., Palmer, J. L., Faunce, D. E. & Kovacs, E. J. An improved cell isolation method for flow cytometric and functional analyses of cutaneous wound leukocytes. J. Immunol. Methods 373, 161–166 (2011).

Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172, 176–190.e19 (2018).

Servettaz, A. et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J. Immunol. 182, 5855–5864 (2009).

Kavian, N. et al. Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis. Arthritis Rheum. 64, 3430–3440 (2012).

Kavian, N. et al. Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis Rheum. 64, 1990–2000 (2012).

Woessner, J. F. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93, 440–447 (1961).

Witko-Sarsat, V. et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49, 1304–1313 (1996).

Manzanero, S. Generation of mouse bone marrow-derived macrophages. Methods Mol. Biol. 844, 177–181 (2012).

Weischenfeldt, J. & Porse, B. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc. 2008, pdb.prot5080 (2008).

Chávez-Galán, L., Vesin, D., Martinvalet, D., Garcia, I. & Low Dose, B. C. G. Infection as a model for macrophage activation maintaining cell viability. J. Immunol. Res. 2016, 4048235 (2016).

Fu, Y. et al. Network topologies and dynamics leading to endotoxin tolerance and priming in innate immune cells. PLoS Comput. Biol. 8, e1002526 (2012).

Deng, H., Maitra, U., Morris, M. & Li, L. Molecular mechanism responsible for the priming of macrophage activation. J. Biol. Chem. 288, 3897–3906 (2013).

van den Hoogen, F. et al. classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheumatol. 65, 2737–2747 (2013).